-
Je něco špatně v tomto záznamu ?
Introduction of a second MenB vaccine into Europe - needs and opportunities for public health
J. Findlow, C. Nuttens, P. Kriz,
Jazyk angličtina Země Anglie, Velká Británie
Typ dokumentu časopisecké články, práce podpořená grantem, přehledy
- MeSH
- dítě MeSH
- lidé MeSH
- meningokokové infekce epidemiologie mikrobiologie prevence a kontrola MeSH
- meningokokové vakcíny aplikace a dávkování imunologie MeSH
- Neisseria meningitidis séroskupiny B imunologie MeSH
- očkovací programy MeSH
- vakcinace metody MeSH
- veřejné zdravotnictví MeSH
- Check Tag
- dítě MeSH
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- přehledy MeSH
- Geografické názvy
- Evropa MeSH
INTRODUCTION: Invasive meningococcal disease (IMD) can be devastating; it is associated with high case fatality rates and long-term sequelae among many survivors. Five serogroups (A, B, C, W, and Y) cause nearly all IMD cases worldwide, and serogroup B (MenB) is the most prevalent in Europe. The European Medicines Agency approved the use of MenB-fHbp (Trumenba®; Pfizer Ltd, Sandwich, UK) in individuals ≥10 years of age for the prevention of MenB IMD in May 2017. MenB-fHbp contains two lipidated recombinant fHbp variants from two different fHbp subfamilies that help provide broad coverage against circulating meningococcal strains and may also improve antibody response compared to a nonlipidated antigen. AREAS COVERED: This review summarizes the latest epidemiology evaluating the disease burden of MenB in Europe, introduces MenB-fHbp (the vaccine most recently approved in the European Union for the prevention of MenB IMD), and provides an overview of its development. EXPERT OPINION: MenB is by far the most prevalent meningococcal serogroup in Europe, and its epidemiology is not currently addressed by European immunization recommendations. New strategies to prevent MenB IMD in Europe will continue to develop with the growing use of vaccines to prevent MenB disease, with increasing support through national immunization programs.
b Medical and Scientific Affairs International Developed Markets Pfizer Paris France
c Centre for Epidemiology and Microbiology National Institute of Public Health Prague Czech Republic
Medical and Scientific Affairs International Developed Markets Pfizer Limited Tadworth UK
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc19027763
- 003
- CZ-PrNML
- 005
- 20190819114101.0
- 007
- ta
- 008
- 190813s2019 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1080/14760584.2019.1578217 $2 doi
- 035 __
- $a (PubMed)30821535
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Findlow, Jamie $u a Medical & Scientific Affairs - International Developed Markets , Pfizer Limited , Tadworth , UK.
- 245 10
- $a Introduction of a second MenB vaccine into Europe - needs and opportunities for public health / $c J. Findlow, C. Nuttens, P. Kriz,
- 520 9_
- $a INTRODUCTION: Invasive meningococcal disease (IMD) can be devastating; it is associated with high case fatality rates and long-term sequelae among many survivors. Five serogroups (A, B, C, W, and Y) cause nearly all IMD cases worldwide, and serogroup B (MenB) is the most prevalent in Europe. The European Medicines Agency approved the use of MenB-fHbp (Trumenba®; Pfizer Ltd, Sandwich, UK) in individuals ≥10 years of age for the prevention of MenB IMD in May 2017. MenB-fHbp contains two lipidated recombinant fHbp variants from two different fHbp subfamilies that help provide broad coverage against circulating meningococcal strains and may also improve antibody response compared to a nonlipidated antigen. AREAS COVERED: This review summarizes the latest epidemiology evaluating the disease burden of MenB in Europe, introduces MenB-fHbp (the vaccine most recently approved in the European Union for the prevention of MenB IMD), and provides an overview of its development. EXPERT OPINION: MenB is by far the most prevalent meningococcal serogroup in Europe, and its epidemiology is not currently addressed by European immunization recommendations. New strategies to prevent MenB IMD in Europe will continue to develop with the growing use of vaccines to prevent MenB disease, with increasing support through national immunization programs.
- 650 _2
- $a dítě $7 D002648
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a očkovací programy $7 D017589
- 650 _2
- $a meningokokové infekce $x epidemiologie $x mikrobiologie $x prevence a kontrola $7 D008589
- 650 _2
- $a meningokokové vakcíny $x aplikace a dávkování $x imunologie $7 D022401
- 650 _2
- $a Neisseria meningitidis séroskupiny B $x imunologie $7 D038541
- 650 _2
- $a veřejné zdravotnictví $7 D011634
- 650 _2
- $a vakcinace $x metody $7 D014611
- 651 _2
- $a Evropa $7 D005060
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 655 _2
- $a přehledy $7 D016454
- 700 1_
- $a Nuttens, Charles $u b Medical & Scientific Affairs - International Developed Markets , Pfizer , Paris , France.
- 700 1_
- $a Kriz, Paula $u c Centre for Epidemiology and Microbiology - National Institute of Public Health , Prague , Czech Republic.
- 773 0_
- $w MED00174438 $t Expert review of vaccines $x 1744-8395 $g Roč. 18, č. 3 (2019), s. 225-239
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/30821535 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20190813 $b ABA008
- 991 __
- $a 20190819114335 $b ABA008
- 999 __
- $a ok $b bmc $g 1432912 $s 1066223
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2019 $b 18 $c 3 $d 225-239 $e 20190301 $i 1744-8395 $m Expert review of vaccines $n Expert Rev Vaccines $x MED00174438
- LZP __
- $a Pubmed-20190813
